Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: Merck & Co. tells Scrip oncology will remain a key priority; J&J is responsibly cautious on growth; Takeda pays big for HutchMed drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 27 January 2023, including: Merck & Co., Inc. tells Scrip oncology will remain a key priority; Johnson & Johnson is responsibly cautious on growth; Takeda Pharmaceutical Co. Ltd. pays big for HUTCHMED (China) Limited drug; industry looks at likely US IRA impact; and lecanemab misses out on EU fast-track treatment.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position" - Scrip, 19 Jan, 2023.)
(Also see "J&J Lays Out ‘Responsibly Cautious’ Growth Outlook" - Scrip, 24 Jan, 2023.)
(Also see "Takeda Pays Big For De-Risked HutchMed CRC Drug" - Scrip, 23 Jan, 2023.)
(Also see "Industry Looks At IRA Drawbacks And Silver Linings" - Scrip, 20 Jan, 2023.)
(Also see "No Fast Track For Lecanemab In EU Disappoints Eisai" - Scrip, 19 Jan, 2023.)